Long non‐coding RNA MALAT1 regulates angiogenesis following oxygen‐glucose deprivation/reoxygenation

Chengya Wang, Youyang Qu, Rui Suo, Yulan ZhuJournal of Cellular and Molecular Medicine 2019 · DOI

TL;DR

This study reveals that the long non-coding RNA MALAT1 plays a crucial role in promoting angiogenesis after ischemic stroke. By investigating its mechanism, researchers found that MALAT1 regulates this process through the 15-LOX1/STAT3 signaling pathway, offering a potential therapeutic target for stroke recovery.

What Problem Does This Paper Address?

Stroke, a leading cause of death and disability, often results from a disruption in blood supply to the brain. While treatments exist for acute ischemic stroke, many patients miss the optimal window for intervention. Understanding the underlying mechanisms of stroke, particularly those related to recovery processes like angiogenesis (the formation of new blood vessels), is critical for developing better therapies. Angiogenesis is vital for restoring blood flow to damaged brain tissue after a stroke. However, the specific roles and molecular mechanisms of long non-coding RNAs (lncRNAs), a class of RNA molecules with regulatory functions, in post-stroke angiogenesis remain largely unknown. This paper aims to elucidate the function and mechanism of MALAT1, a specific lncRNA, in this process.

Methods

The researchers employed a multi-pronged approach combining in vivo and in vitro experiments.

  • Animal Model: A focal cerebral ischemia model was created in mice by occluding the middle cerebral artery (MCAO) followed by reperfusion. This mimicked the conditions of ischemic stroke.
  • Cell Culture Model: A mouse brain microvascular endothelial cell (BMEC) line was used to create an in vitro model of oxygen-glucose deprivation/reoxygenation (OGD/R), simulating the cellular stress experienced during stroke.
  • Gene Manipulation: Lentiviruses were used to knock down the expression of MALAT1 in BMECs, allowing researchers to study the consequences of reduced MALAT1 levels.
  • Functional Assays:
    • Cell Viability (MTT assay): To assess how OGD/R and MALAT1 manipulation affected cell survival.
  • Cell Proliferation (Cell Cycle Analysis): To determine the impact on cell division.
  • Cell Migration (Scratch Assay): To measure the ability of cells to move and cover a wound, indicative of angiogenic potential.
  • Immunohistochemistry and Immunofluorescence: To visualize and quantify the expression of key proteins like VEGF and CD31 (a marker for endothelial cells and new blood vessels).
  • Molecular Analysis:
    • Quantitative Real-Time PCR (qRT-PCR): To measure the mRNA levels of MALAT1, 15-LOX1, VEGF, and STAT3.
  • Western Blot Analysis: To assess the protein levels of 15-LOX1, VEGF, STAT3, and phosphorylated STAT3 (pSTAT3).
  • Enzyme-Linked Immunosorbent Assay (ELISA): To quantify the levels of 15-HETE, a metabolite of 15-LOX1.
  • Fluorescence In Situ Hybridization (FISH): To determine the localization of MALAT1 within cells.
  • Signaling Pathway Inhibition: Specific inhibitors were used to block the activity of STAT3 (Stattic) and 15-LOX1 (PD146176) to dissect their roles in the observed angiogenesis.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • MALAT1 is a key player in post-stroke angiogenesis: The study strongly suggests that MALAT1 is not just present but actively promotes the formation of new blood vessels after ischemic injury.
  • Hypoxia/Ischemia upregulates MALAT1: Both in vivo (stroke model) and in vitro (OGD/R) conditions lead to increased MALAT1 expression, indicating its role in the body's response to such insults.
  • MALAT1's pro-angiogenic mechanism is complex: It doesn't act alone but influences a cascade involving 15-LOX1, STAT3, and VEGF.
  • 15-LOX1 acts upstream of STAT3: The findings point to 15-LOX1 as an initiator that leads to the activation (phosphorylation) of STAT3, which in turn influences VEGF. This is a novel mechanistic insight.
  • Therapeutic potential: By identifying MALAT1 and its downstream pathway as critical for angiogenesis, the study opens doors for developing new treatments to enhance stroke recovery.

Key Results

  • Increased MALAT1 in stroke: MALAT1 expression was significantly upregulated in both mouse brain tissue after MCAO and in endothelial cells subjected to OGD/R.
  • MALAT1 knockdown impairs angiogenesis: Reducing MALAT1 levels in endothelial cells significantly decreased their viability, proliferation, migration, and CD31 expression, all indicators of reduced angiogenic capacity.
  • Pathway involvement: Knockdown of MALAT1 led to reduced expression of 15-LOX1, VEGF, and pSTAT3.
  • 15-LOX1/STAT3/VEGF axis: Inhibition of STAT3 with Stattic reduced VEGF but not 15-LOX1. Conversely, inhibition of 15-LOX1 with PD146176 reduced both pSTAT3 and VEGF, suggesting 15-LOX1 is upstream of STAT3.
  • MALAT1 promotes CD31 expression: MALAT1 knockdown also reduced the number of CD31-positive endothelial cells, further supporting its role in microvessel formation.

Limitations and Future Work

  • Direct MALAT1 targets: The paper acknowledges that while MALAT1's influence on the 15-LOX1/STAT3/VEGF pathway is shown, the direct molecular targets of MALAT1 remain to be fully elucidated.
  • miRNA involvement: The authors suggest that MALAT1 might act as a competing endogenous RNA (ceRNA) by sponging microRNAs (miRNAs), a mechanism observed in other contexts. Investigating the role of specific miRNAs in MALAT1-mediated angiogenesis following I/R is a promising future direction.
  • Clinical translation: While the findings suggest therapeutic potential, further research is needed to translate these discoveries into clinical applications for stroke patients.
  • Broader implications: The study focuses on stroke, but the role of MALAT1 in angiogenesis might extend to other conditions involving vascular repair or disease.

Summary updated

Abstract

Long non-coding RNAs (lncRNAs) have been identified as playing critical roles in multiple diseases. However, little is known regarding their roles and mechanisms in post-stroke angiogenesis. Our studies focused on deciphering the functional roles and the underlying mechanisms of the lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in the process of angiogenesis following oxygen-glucose deprivation/reoxygenation (OGD/R). We characterized the up-regulation of MALAT1 expression in the process of angiogenesis after hypoxic injury in vivo and in vitro. We further showed that compared with the empty vector, MALAT1 knockdown had significantly reduced the capacity for angiogenesis, which was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT), scratching, cell cycle and immunofluorescent staining. Thus, our findings suggest that MALAT1 may mediate proangiogenic function in OGD/R. To further explore the potential mechanisms, we used lentiviruses expressing shMALAT1 and empty vector; the results revealed that shMALAT1 reduced the expression of 15-lipoxygenase 1 (15-LOX1), vascular endothelial growth factor (VEGF) and the phosphorylation of signal transducers and activators of transcription 3 (pSTAT3). Taken together, our results are the first to propose that MALAT1 may regulate angiogenesis through the 15-LOX1/STAT3 signalling pathway, and they may provide a critical target for the treatment of hypoxic injury and an avenue for therapeutic angiogenesis.
BibTeX
@article{wang2019long,
  author = {Chengya Wang and Youyang Qu and Rui Suo and Yulan Zhu},
  title = {{Long non‐coding RNA MALAT1 regulates angiogenesis following oxygen‐glucose deprivation/reoxygenation}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2019},
  doi = {10.1111/jcmm.14204},
}
Figure